ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Avirmax Inc., will make three scientific presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Salt Lake City, Utah, May 4 - 8, 2025. ARVO is the ...

Dengue’s rise in 2024, influenced by climate change and shifting serotypes, underscores the need for effective vaccines to ...

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...

The fight continues against the invasive spread of wild boar in Alberta and its inherent disease risk and damage to the ...

International Business Machines Corporation ( NYSE: IBM) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Olympia McNerney - Global Head of IR Arvind Krishna - Chairman, President and CEO ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its ...

AppLovin shares have recently been in the spotlight, but not in a good way. Check out why I rate APP stock a buy.

Zuckerberg worried about Google diving into social media, and created a competitive buffer around Meta through M&A, according ...

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients ...